Showing papers by "Susumu Kobayashi published in 2017"
TL;DR: Conurrent mutations, specifically TP53, are common in EGFR mutated lung cancer and may altered clinical outcomes and may alter clinical outcomes.
143 citations
TL;DR: Three biomarker‐specified groups of advanced lung adenocarcinomas can be defined, each paired with a specific palliative first‐line systemic therapy of proven clinical benefit.
110 citations
TL;DR: In this article, Li6.6La3Zr1.4O12 [LLZ(Ta0.4)] with high sintering density at 25, 60, and 100°C.
76 citations
TL;DR: The first enantioselective total synthesis of (+)-iso-A82775C (18 steps, 2.2% overall yield) toward the eventual biomimetictotal synthesis of chloropupukeananin is described.
33 citations
TL;DR: ADCmin and maximum diameter of solid components were useful for differentiating BOTs from MEOTs.
24 citations
TL;DR: The meta-analysis suggested that membranous, cytoplasmic and nuclear β-catenin all could serve as an important prognosticator for patients with NSCLC.
Abstract: Background: β-catenin is a key component of the canonical Wnt pathway, which plays pivotal roles in malignant transformation and cancer progression. Several studies have reported the clinical significance of the expression level of β-catenin in different subcellular locations. This meta-analysis aimed to assess the prognostic value of β-catenin expression patterns in patients with non-small cell lung cancer (NSCLC).
Methods: PubMed and Embase databases were searched to identify all articles referring to the association between β-catenin expression level and outcomes of patients of NSCLC up to November 2016. We included eligible studies to summarize the extracted data in terms of pooled hazard ratios (HRs) and their 95% confidence intervals (95% CIs).
Results: A total of 24 studies published between 2000 and 2016 were eligible for this meta-analysis. The total number of patients with NSCLC included was 2,807. Pooled HRs and 95% CIs suggested that positive β-catenin expression in membrane was associated with higher survival rates (HR: 0.53; 95% CI: 0.32–0.87), whereas β-catenin expression in cytoplasm and nucleus had unfavorable impacts on survival rates with HR of 1.63 (95% CI: 1.34–1.99) and HR of 3.15 (95% CI: 1.97–5.05), respectively. But, there was no significant association between β-catenin expression in abnormal pattern with prognosis (HR: 1.38; 95% CI: 0.61–3.15). Publication bias was absent in all of the four outcomes. Sensitivity analysis revealed that the results of this meta-analysis were robust.
Conclusions: Reduced membranous β-catenin, positive expression of cytoplasmic or nuclear β-catenin is all correlated with poor prognosis, although we did not identify a significant association between abnormal β-catenin expression and clinical outcome of NSCLC patients. The meta-analysis suggested that membranous, cytoplasmic and nuclear β-catenin all could serve as an important prognosticator for patients with NSCLC.
23 citations
National University of Singapore1, Harvard University2, Charles University in Prague3, Beth Israel Deaconess Medical Center4, Ohio State University5, University of Alabama at Birmingham6, National Research Council7, Albert Einstein College of Medicine8, Johns Hopkins University9, University of Queensland10
TL;DR: An evolutionarily conserved octameric sequence, CCCAGCAG, is identified, ∼100 bases upstream of the CEBPA transcription start site, and it is demonstrated through mutational analysis that this sequence is crucial for C/EBPα expression.
19 citations
12 citations
TL;DR: An epoxide-free analog called (S)-β-salicyloylamino-α-exo-methylene-ƴ-butyrolactone (SEMBL) is designed and synthesized and has a potential to be a candidate for a new anti-inflammatory and anticancer agent.
10 citations
TL;DR: In this article, a highly convergent total synthesis of (+)-methynolide, based on two types of stereoselective aldol reaction, was achieved.
10 citations
TL;DR: The study indicated that high levels of AGEs were independently associated with hearing impairment, and modifying levels with a focus on pure tone average may prevent hearing impairment.
TL;DR: The results indicate that gefitinib may work as a mitochondrial protector against combinational treatment with mitochondria-dependent anticancer agents in high-cell-density.
Abstract: Background/aim Gefitinib is a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and has been approved for the treatment of non-small cell lung cancers (NSCLCs) with EGFR mutations. Here we demonstrated that gefitinib induced a significantly enhanced biological activity of succinate-tetrazolium reductase (STR) in mitochondria and mitochondrial membrane potential in HCC827 cells (EGFR mutation NSCLCs, sensitive to gefitinib) at a high cell density. Materials and methods We assessed the biological activity (STR, mitochondrial membrane potential, expression level of Bcl-2 family proteins) of gefitinib on NSCLCs at different cell densities. Results The 3D cell culture experiments showed the enhanced mitochondrial biological activity in clustered cell culture treated with gefitinib. Interestingly, the expression levels of Bcl-xL and Bax, were affected by the cellular number and gefitinib treatment. We also found that gefitinib prevented additive anticancer activity in the combinational treatment with doxorubicin, which induces mitochondria-dependent apoptotic cell death. Conclusion Our results indicate that gefitinib may work as a mitochondrial protector against combinational treatment with mitochondria-dependent anticancer agents in high-cell-density.